[
    [
        {
            "time": "2020-04-24",
            "original_text": "早间公告2020年4月24日星期五 泰格医药(300347.SZ)已向港交所递交IPO申请",
            "features": {
                "keywords": [
                    "泰格医药",
                    "IPO",
                    "港交所",
                    "上市申请"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "早间公告2020年4月24日星期五 泰格医药(300347.SZ)已向港交所递交IPO申请",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-04-24",
            "original_text": "早间公告：金财互联下修业绩快报；泰格医药递交港股上市申请",
            "features": {
                "keywords": [
                    "泰格医药",
                    "港股",
                    "上市申请",
                    "金财互联",
                    "业绩快报"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技",
                    "互联网金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "早间公告：金财互联下修业绩快报；泰格医药递交港股上市申请",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "新股前瞻|业绩增速明显下滑，泰格医药仍想A、H股“一把抓” 盈利能力下降",
            "features": {
                "keywords": [
                    "泰格医药",
                    "A股",
                    "H股",
                    "盈利能力",
                    "业绩增速下滑"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "新股前瞻|业绩增速明显下滑，泰格医药仍想A、H股“一把抓” 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "新股消息 | 方达控股(01521)母公司泰格医药递表港交所主板 为中国最大的临床合同研究机构",
            "features": {
                "keywords": [
                    "泰格医药",
                    "方达控股",
                    "港交所",
                    "临床研究"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "新股消息 | 方达控股(01521)母公司泰格医药递表港交所主板 为中国最大的临床合同研究机构",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "泰格医药：已向港交所递交发行上市申请材料",
            "features": {
                "keywords": [
                    "泰格医药",
                    "港交所",
                    "上市申请"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "泰格医药：已向港交所递交发行上市申请材料",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "泰格医药向香港联交所递交境外上市外资股（H股）上市申请",
            "features": {
                "keywords": [
                    "泰格医药",
                    "H股",
                    "上市申请",
                    "香港联交所"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "泰格医药向香港联交所递交境外上市外资股（H股）上市申请",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "泰格医药现4笔大宗交易 共成交8,024.53万元",
            "features": {
                "keywords": [
                    "泰格医药",
                    "大宗交易",
                    "成交金额"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药现4笔大宗交易 共成交8,024.53万元",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【IPO追踪】泰格医药(300347-CN)传来港上市筹78亿",
            "features": {
                "keywords": [
                    "泰格医药",
                    "IPO",
                    "港上市",
                    "筹资金额"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【IPO追踪】泰格医药(300347-CN)传来港上市筹78亿",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]